The benchmark S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has followed the lead of international markets and in afternoon trade finds itself down a disappointing 0.8% to 5,730 points.
Four shares which haven’t let this hold them back are listed below. Here’s why they are finishing the week with a bang:
The Pro Medicus Limited (ASX: PME) share price has climbed 4% to $5.10 after the healthcare software company released its preliminary final results. Despite the impact of currency headwinds, Pro Medicus delivered an impressive 46.4% lift in net profit after tax to $9.3 million. I think this solid result and its positive outlook could mean the company is worth considering as a buy and hold investment.
The Bubs Australia Ltd (ASX: BUB) share price has rebounded from yesterday’s heavy decline and is up 6.5% to 65 cents. This morning the baby food and infant formula company announced the appointment of Dennis Lin as Chairman of the Bubs Australia Board. Mr Lin is also a partner at BDO, where he leads the firm’s China Advisory Services team. Investors appear to believe this experience will be very useful given Bubs’ aim of penetrating the lucrative Chinese infant formula market.
The Kogan.com Ltd (ASX: KGN) share price is up 6% to $2.54 following the release of its full-year results. The online retailer smashed its prospectus forecasts and reported pro forma net profit after tax growth of 800% to $7.2 million. This was driven by a 30% increase in its customer base and strong growth from its private label products.
The Tatts Group Limited (ASX: TTS) share price is up 3.5% to $4.16 thanks partly to a research note out of Deutsche Bank. According to the note, its analysts have retained their buy rating and $4.67 price target following the release of the lottery operator’s full-year results. Tatts delivered a result ahead of Deutsche’s expectations.
Missed these gains? Don't worry, these growth shares could be next in line for big gains in my opinion.
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2017."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.